Core Viewpoint - Yiling Pharmaceutical (002603.SZ) announced that its wholly-owned subsidiary, Hengtai Wanyang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor used for treating type 2 diabetes [1]. Group 1 - Yiling Pharmaceutical's subsidiary, Hengtai Wanyang, has successfully obtained a marketing approval for Dapagliflozin [1]. - Dapagliflozin is characterized as a highly selective and reversible SGLT-2 inhibitor that blocks glucose reabsorption in the renal proximal tubule, promoting urinary glucose excretion to lower blood sugar levels [1].